Vistagen's Fasedienol Meets Key ICH E1 Safety Milestones with Over 1,500 Subjects
Summary
Vistagen's fasedienol nasal spray program has met ICH E1 minimum patient safety exposure recommendations, with over 1,500 subjects exposed, including long-term data. This news reports on the 8-K filed earlier today and follows the completion of the PALISADE-4 Phase 3 trial's randomized portion in early May and preliminary positive safety data from its open-label extension. Meeting these safety milestones is a critical step for building a robust safety profile required for a potential New Drug Application. However, the company still needs to align with the FDA on specific patient exposure requirements for NDA submission. Topline results for PALISADE-4 are expected in Q2 2026, and Phase 2 Repeat Dose results in Q3 2026.
At the time of this announcement, VTGN was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.